NHIC

NewHold Investment Corp III

Pullback / Mixed

Near 52W High

$10.60+$0.00 (+0.00%)

After Hours:$10.60+$0.00 (+0.00%)

Loading Chart...

Institutional Signal // Day Trade Edge:Neutral / No Active Setup Today

Key Statistics

Market Cap292.7M

Forward P/E—

EPS (TTM)$-0.01

52-Week Return+4.02%

50-Day Moving Avg$10.78

200-Day Moving Avg$10.55

Volume Today147.25K

Avg Volume317.09K

Day Range$10.58 – $10.62

52-Week Range$10.16 – $11.60

Open Price$10.60

Previous Close$10.60

Company Profile

No profile description available.

Exchange Listing

NHIC

Key Statistics

Company Profile

Company Profile

Recent News

Recent News

Company Profile

Recent News

NHIC

Key Statistics

Company Profile

Company Profile

Recent News

newcleo-Led Consortium Awarded Funding to Develop Floating Nuclear for the Decarbonisation of the French Maritime Sector

NewHold Investment Corp. III and newcleo Ltd. Announce Effectiveness of Registration Statement on Form F-4 with the SEC in Connection With Proposed Business Combination and Nasdaq Listing

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

Narayana Hrudayalaya Ltd (BOM:539551) (Q1 2027) Earnings Call Highlights: Insurance Losses ...

NewHold, newcleo Report Registration Statement Filing for Merger

newcleo advances MOX fuel licensing in France and enters new collaboration phase with French authorities

NewHold Investment Corp. III and newcleo Ltd. Announce Filing of Registration Statement on Form F-4 with the SEC in Connection With Proposed Business Combination

APRW's 30 years filled with regional and global integrated communications success in national campaigns, well-loved brands, entertainment and festivals, education, startups, charities and more

Recent News

Company Profile

Recent News

newcleo-Led Consortium Awarded Funding to Develop Floating Nuclear for the Decarbonisation of the French Maritime Sector

NewHold Investment Corp. III and newcleo Ltd. Announce Effectiveness of Registration Statement on Form F-4 with the SEC in Connection With Proposed Business Combination and Nasdaq Listing

Cirrus Therapeutics Strengthens Its Position as a Next-Generation Global Ocular Immunology Leader with Singapore Eye Research Institute (SERI) Collaboration and Additional Financing

Narayana Hrudayalaya Ltd (BOM:539551) (Q1 2027) Earnings Call Highlights: Insurance Losses ...

NewHold, newcleo Report Registration Statement Filing for Merger

newcleo advances MOX fuel licensing in France and enters new collaboration phase with French authorities

NewHold Investment Corp. III and newcleo Ltd. Announce Filing of Registration Statement on Form F-4 with the SEC in Connection With Proposed Business Combination

APRW's 30 years filled with regional and global integrated communications success in national campaigns, well-loved brands, entertainment and festivals, education, startups, charities and more